Patients over age 65 with myelodysplastic syndromes (MDS) should be considered transplant eligible, according to an oral presentation at the 2015 ASH Annual Meeting. Investigators reported the results of a multi-center, prospective study comparing HCT outcomes of 592 patients with MDS age 55-64 years and 688 patients age ≥65 years who underwent HCT between 2010-2014. Two-year overall survival was comparable in patients age 55-64 years vs. patients age ≥65 years: 46% vs. 42%, respectively (p=0.1). Transplants were between 2010 and 2014 reported to CIBMTR (Center for International Blood and Marrow Transplant Research), and the 688 patients age ≥65 years were Medicare-eligible patients enrolled in a CIBMTR-sponsored coverage with evidence development (CED) clinical trial approved by the Centers for Medicare and Medicaid services.
Patients Age 65 Years and Older with MDS Should Not Be Limited from Undergoing HCT